- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02330068
Microbiome of Depression & Treatment Response to Citalopram
Microbiome of Depression &Amp; Treatment Response to Citalopram: A Feasibility Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will be conducted at Mayo Clinic Jacksonville Department of Psychiatry (recruit up to 10 patients and 10 controls with paired data) and Mayo Clinic Depression Center in Rochester (recruit up to 30 patients and 30 controls with paired data). Patients with major depression, Bipolar Disorder I or Bipolar Disorder II confirmed by structured diagnostic interview (SCID) and moderate symptom severity (Quick Inventory of Depressive Symptomatology or S-C16) will be enrolled in the 12 week study. We will explore the gut microbiome (and its genetic material) and gut-brain markers of inflammation (cortisol, cytokines) from stool specimens and serum samples, respectively. Collections will be at baseline, week 2, and week 12 of the study. Healthy controls matched for age, sex (including menopausal status of female subjects), and body-mass index (BMI) will have only baseline stool and serum collections. Statistical t-tests will be used to assess baseline differences between patient and controls in microbiome and inflammatory markers. Treatment response (50% reduction in QIDS), treatment remission (QIDS-C16 < 6) will be analyzed with change in microbiome and inflammation markers. Correlational analysis with multiple testing corrections will be conducted between depression symptom severity and measures of cortisol, cytokines, and gut microbiome composition.
This study will focus on early translation of Dr. Fryer and Dr. Chia's research and will bring the gut-brain interface to the field of individualizing treatment to patients who struggle with depression. This project will provide insight into how gut microbiota may be implicated in depression, how antidepressant treatments alter microbiota composition, and how these factors impact key physiologic mediators of depression (i.e. cortisol and cytokine levels). The public health implications of more focused drug development and treatment for depression are substantial.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Outpatients or inpatients with nonpsychotic major depressive disorder (MDD) or Bipolar I or II Disorder.
- A score of >16 on the QIDS
- Outpatients or inpatients for whom antidepressant treatment is deemed appropriate by the treating clinician
- Subjects who are between 18-55 years of age
Exclusion Criteria:
- Contraindications to citalopram treatment
- Axis I or II disorder other than depression that is the primary reason for seeking treatment intervention and/or psychiatric care
- Subjects diagnosed with Borderline Personality Disorder (BPD) as their primary diagnosis.
- For healthy controls, a first degree relative who has been diagnosed with an Axis I disorder
- Patients with schizophrenia, schizoaffective disorder, or bipolar I disorder
- Antidepressant treatment within 4 days of study (1 week if fluoxetine). Subjects currently on antidepressant medication with subtherapeutic results in terms of depression management after providing informed consent, will undergo a medication taper and discontinuation prior to initiation of citalopram treatment. The subject must be off of previous antidepressants for at least 4 days week prior to starting citalopram (1 week if fluoxetine). The subject will be closely monitored by the research study psychiatrist (with or without additional monitoring from primary clinical psychiatric providers). The medication taper is left up to the research study psychiatrist in consultation with patient's primary care or psychiatric provider. Study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study
- Study subjects using their antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis, or other diagnoses will not be eligible for the study unless they remain on a stable dose of the medication for the 12 weeks of the study.
- Trazodone, melatonin, and diphenhydramine may be used as rescue medications for insomnia. Benzodiazepines may be used for treatment of anxiety, not to exceed 4 mg/24 hour of lorazepam
- Subjects who are currently on an antibiotic or an antibiotic within 2 weeks. (Topical antibiotics are OK)
- Daily use of aspirin, NSAID's or Warfarin (low dose of baby aspirin OK)
- Subjects unable to give informed consent are excluded
- Pregnant subjects will be excluded
- Subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded
- Postmenopausal women are not eligible for this study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Controls
Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
|
|
Cases
Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
|
Cases
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The potential differences in the microbiome between depressed patients and healthy controls
Time Frame: Over 12 weeks
|
The gut microbiome of depressed patients is different from that of age-, sex-, menopause-, and BMI-matched healthy controls
|
Over 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiome change in treatment response vs. non-response to citalopram
Time Frame: Over 12 weeks
|
The gut microbiome change of patients that respond to citalopram is different
|
Over 12 weeks
|
Inflammatory markers of depression and their relationship to the microbiome
Time Frame: Over 12 weeks
|
Changes in inflammatory markers of depression correspond to changes in depression symptom severity.
|
Over 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Bobo, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Mood Disorders
- Bipolar and Related Disorders
- Depressive Disorder
- Bipolar Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
- 14-002154
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder, Bipolar I and Bipolar II
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Intra-Cellular Therapies, Inc.RecruitingMajor Depressive Episode Associated With Bipolar I or Bipolar II DisorderUnited States
-
BiogenCompletedBipolar Disorder I | Major Depressive Episode | Bipolar Disorder IIUnited States
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Sunnybrook Health Sciences CentreCompletedSuicidal Ideation | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Bipolar II DisorderCanada
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH)RecruitingMood Disorders | Major Depressive Disorder | Bipolar Disorder I | Bipolar Disorder II | Persistent Depressive Disorder (Dysthymia) | CyclothymiaUnited States
-
Mayo ClinicNational Network of Depression CentersCompletedMajor Depression | Unipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of MinnesotaBrown University; Hennepin County Medical Center, MinneapolisCompletedPsychotic Disorders | Smoking Cessation | Schizophrenia | Major Depressive Disorder | Mental Illness | Cigarette Smoking | Bipolar Disorder I | Bipolar II DisorderUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingDepressive Disorder | Mood Disorders | Anhedonia | Bipolar Disorder | Depressive Disorder, Major | Depressive Disorder, Treatment-Resistant | Bipolar Disorder I | Bipolar Disorder IIUnited Kingdom
Clinical Trials on citalopram
-
A.O. Ospedale Papa Giovanni XXIIIUnknownAcute Appendicitis Without PeritonitisItaly
-
Istituto Auxologico ItalianoRecruiting
-
St. Luke's-Roosevelt Hospital CenterForest LaboratoriesCompleted
-
China Medical University HospitalNational Science Council, TaiwanCompletedDepression | Major Depression | Major Depressive DisorderTaiwan
-
Sunnybrook Health Sciences CentreOntario Mental Health FoundationCompleted
-
Institut National de la Santé Et de la Recherche...Completed
-
Hadassah Medical OrganizationUnknown
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases
-
Mclean HospitalCompletedMajor Depressive Disorder | MDD | CitalopramUnited States
-
Ontario Neurotrauma FoundationUnknown